Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) announced a quarterly dividend on Monday, July 6th. Stockholders of record on Monday, August 31st will be given a dividend of 0.16 per share by the medical instruments supplier on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 31st.
Mesa Laboratories has a payout ratio of 5.2% indicating that its dividend is sufficiently covered by earnings.
Mesa Laboratories Trading Down 2.8%
Shares of NASDAQ:MLAB traded down $2.98 during mid-day trading on Monday, hitting $102.56. The stock had a trading volume of 156,671 shares, compared to its average volume of 218,561. The company’s 50 day moving average is $102.05 and its 200-day moving average is $92.56. Mesa Laboratories has a 12-month low of $55.45 and a 12-month high of $113.99. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72. The company has a market cap of $566.13 million, a PE ratio of 15.45 and a beta of 0.93.
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Further Reading
- Five stocks we like better than Mesa Laboratories
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
